DK1410805T3 - Vaccine mod HPV - Google Patents

Vaccine mod HPV

Info

Publication number
DK1410805T3
DK1410805T3 DK03078635T DK03078635T DK1410805T3 DK 1410805 T3 DK1410805 T3 DK 1410805T3 DK 03078635 T DK03078635 T DK 03078635T DK 03078635 T DK03078635 T DK 03078635T DK 1410805 T3 DK1410805 T3 DK 1410805T3
Authority
DK
Denmark
Prior art keywords
vaccine against
against hpv
hpv
vaccine
Prior art date
Application number
DK03078635T
Other languages
Danish (da)
English (en)
Inventor
Martine Anne Cecil Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of DK1410805T3 publication Critical patent/DK1410805T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09C—RECLAMATION OF CONTAMINATED SOIL
    • B09C1/00—Reclamation of contaminated soil
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02D—FOUNDATIONS; EXCAVATIONS; EMBANKMENTS; UNDERGROUND OR UNDERWATER STRUCTURES
    • E02D3/00—Improving or preserving soil or rock, e.g. preserving permafrost soil
    • E02D3/11—Improving or preserving soil or rock, e.g. preserving permafrost soil by thermal, electrical or electro-chemical means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK03078635T 1999-09-07 2000-09-07 Vaccine mod HPV DK1410805T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9921146A GB9921146D0 (en) 1999-09-07 1999-09-07 Novel composition
EP20000967654 EP1210113B1 (en) 1999-09-07 2000-09-07 Combined vaccine compositions

Publications (1)

Publication Number Publication Date
DK1410805T3 true DK1410805T3 (da) 2006-04-18

Family

ID=10860520

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03078635T DK1410805T3 (da) 1999-09-07 2000-09-07 Vaccine mod HPV
DK00967654T DK1210113T3 (da) 1999-09-07 2000-09-07 Kombinerede vaccinepræparater

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK00967654T DK1210113T3 (da) 1999-09-07 2000-09-07 Kombinerede vaccinepræparater

Country Status (33)

Country Link
US (3) US6936255B1 (no)
EP (3) EP1410805B1 (no)
JP (2) JP4689910B2 (no)
KR (2) KR100557665B1 (no)
CN (2) CN1325117C (no)
AR (1) AR025502A1 (no)
AT (2) ATE312624T1 (no)
AU (1) AU766494B2 (no)
BR (1) BR0014171A (no)
CA (2) CA2443214C (no)
CO (1) CO5280045A1 (no)
CY (2) CY1107457T1 (no)
CZ (2) CZ302811B6 (no)
DE (2) DE60027029T2 (no)
DK (2) DK1410805T3 (no)
ES (2) ES2253636T3 (no)
GB (1) GB9921146D0 (no)
GC (1) GC0000201A (no)
HK (2) HK1064958A1 (no)
HU (2) HU229099B1 (no)
IL (3) IL158107A0 (no)
MX (1) MXPA02002484A (no)
MY (2) MY142842A (no)
NO (3) NO332800B1 (no)
NZ (2) NZ527560A (no)
PL (2) PL201264B1 (no)
PT (1) PT1210113E (no)
SG (1) SG110072A1 (no)
SI (2) SI1410805T1 (no)
TR (1) TR200200607T2 (no)
TW (1) TWI258374B (no)
WO (1) WO2001017551A2 (no)
ZA (2) ZA200306402B (no)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20060029617A1 (en) * 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
DE69932717T2 (de) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
PL201482B1 (pl) 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
ATE354662T1 (de) * 2001-03-23 2007-03-15 Deutsches Krebsforsch Modifizierte hpv e6- und e7-gene und -proteine als impfstoff
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
AU2003232951B2 (en) † 2002-05-17 2009-07-23 University Of Cape Town Chimaeric human papillomavirus 16 L1 proteins comprising an L2 peptide, virus-like particles prepared therefrom and a method for preparing the particles.
CN1650012A (zh) 2002-07-24 2005-08-03 英特塞尔股份公司 来自致病病毒的备选阅读框所编码的抗原
CA2484339A1 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
CN100418577C (zh) * 2002-12-20 2008-09-17 葛兰素史密丝克莱恩生物有限公司 Hpv-16和hpv-18l1vlp疫苗
EA009179B1 (ru) * 2002-12-20 2007-12-28 Глаксосмитклайн Байолоджикалс С.А. Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
CN100355453C (zh) * 2003-03-24 2007-12-19 英特塞尔股份公司 改进的疫苗
US7704514B2 (en) 2003-03-24 2010-04-27 Intercell Ag Vaccines
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
WO2005123125A1 (en) * 2004-06-16 2005-12-29 Glaxosmithkline Biologicals S.A. Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
GB0413510D0 (en) * 2004-06-16 2004-07-21 Glaxosmithkline Biolog Sa Vaccine
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
EP1850871A2 (en) * 2005-02-16 2007-11-07 Novartis Vaccines and Diagnostics, Inc. Adjuvant composition comprising aluminium phosphate and 3d-mpl
JP4182074B2 (ja) 2005-03-03 2008-11-19 ファナック株式会社 ハンド及びハンドリングロボット
AU2006226543B2 (en) * 2005-03-23 2011-10-06 Glaxosmithkline Biologicals S.A. Use of an influenza virus an oil-in-water emulsion adjuvant to induce CD4 T-cell and/or improved B-memory cell response
KR20080005585A (ko) * 2005-04-26 2008-01-14 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
AR053715A1 (es) * 2005-04-26 2007-05-16 Glaxosmithkline Biolog Sa Vacuna multivalente de vph
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US7790203B2 (en) * 2005-12-13 2010-09-07 Lowder Tom R Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
PL1968630T3 (pl) 2005-12-29 2018-08-31 Boehringer Ingelheim Vetmedica, Inc. Multiwalentne immunogenne kompozycje PCV2
DK3127551T3 (da) 2005-12-29 2020-10-12 Boehringer Ingelheim Animal Health Usa Inc Pcv2-immunogen-sammensætning til at mindske kliniske symptomer i grise
WO2008027394A2 (en) 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
EP2486938B1 (en) 2006-09-26 2018-05-09 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
JP2010520874A (ja) 2007-03-09 2010-06-17 メルク・シャープ・エンド・ドーム・コーポレイション パピローマウイルスワクチン組成物
NZ582271A (en) * 2007-06-26 2012-03-30 Japan Health Science Found Vaccine antigen capable of inducing cross-reacting and neutralizing antibody against high-risk-type human papillomavirus
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
US9114098B2 (en) 2008-06-04 2015-08-25 The Chemo-Sero-Therapeutic Research Institute Method for using inactivated Japanese encephalitis virus particles as adjuvant
SI2318042T1 (sl) * 2008-07-31 2014-12-31 Glaxosmithkline Biologicals S.A. Cepivo proti HPV
RU2585961C9 (ru) 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
TWI494125B (zh) 2009-06-05 2015-08-01 Infectious Disease Res Inst 合成的葡萄吡喃糖基脂質佐劑
EP2444103B1 (en) * 2009-06-19 2017-12-20 Eyegene Inc. Vaccine for cervical cancer
EA022213B1 (ru) * 2009-06-25 2015-11-30 Глаксосмитклайн Байолоджикалс С.А. Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
US10456463B2 (en) * 2010-05-28 2019-10-29 Zoetis Belgium S.A Vaccines comprising cholesterol and CpG as sole adjuvant-carrier molecules
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
HUE028877T2 (en) * 2010-08-27 2017-01-30 Intervet Int Bv Test of biological activity of vaccine formulation
CN102008721A (zh) * 2010-11-16 2011-04-13 浙江大学 一种hpv多肽/dc混合疫苗及其制备
AU2011336894B2 (en) 2010-11-24 2016-11-17 Genocea Biosciences, Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
JP6054942B2 (ja) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
CN102210858B (zh) * 2011-05-18 2013-05-08 北京科兴生物制品有限公司 一种肠道病毒71型与甲型肝炎联合疫苗
CA2834618C (en) 2011-06-24 2020-11-03 Merck Sharp & Dohme Corp. Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
AU2012279154A1 (en) * 2011-07-01 2014-02-20 The Regents Of The University Of California Herpes virus vaccine and methods of use
US9624273B2 (en) 2011-11-23 2017-04-18 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US11510875B2 (en) 2012-02-07 2022-11-29 Access To Advanced Health Institute Adjuvant formulations comprising TLR4 agonists and methods of using the same
BR112014028476A2 (pt) 2012-05-16 2017-08-01 Immune Design Corp fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
EA032326B1 (ru) 2013-04-18 2019-05-31 Иммьюн Дизайн Корп. Монотерапия gla для применения в лечении рака
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
AU2014373928C1 (en) 2013-12-31 2020-12-17 Access To Advanced Health Institute Single vial vaccine formulations
WO2018026547A1 (en) 2016-08-01 2018-02-08 The Wistar Institute Of Anatomy And Biology Compositions and methods of replication deficient adenoviral vectors for vaccine applications
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド ヘルペスを処置するための方法および組成物
CN107987159B (zh) * 2017-11-28 2021-06-22 上海药明生物医药有限公司 一种使用大剂量dna免疫技术免疫动物使血清中抗体滴度提高的方法
GB201821207D0 (en) * 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
CN110576034B (zh) * 2019-10-09 2020-06-30 北京尚华生态环保科技股份公司 一种土壤原位修复方法
CN110652980B (zh) * 2019-10-09 2020-06-30 北京尚华生态环保科技股份公司 一种土壤原位修复剂
WO2021097347A1 (en) 2019-11-15 2021-05-20 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
CN114681602B (zh) * 2020-12-25 2023-12-01 中国食品药品检定研究院 一种双价人乳头瘤病毒疫苗

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085804B2 (ja) * 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
DE122007000018I1 (de) * 1991-07-19 2007-05-24 Univ Queensland Polynukleotidabschnitt des HPV16-Genoms
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
AU685443B2 (en) * 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9409962D0 (en) * 1994-05-18 1994-07-06 Smithkline Beecham Biolog Novel compounds
WO1996026277A1 (en) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
EP0877809A1 (en) * 1996-01-26 1998-11-18 Innogenetics N.V. TOXOPLASMA GONDII ANTIGEN Tg20
EP0879060B1 (en) * 1996-02-09 2008-03-26 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines against varicella zoster virus gene 63 product
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
CA2229955C (en) * 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
KR20010041629A (ko) * 1998-03-09 2001-05-25 장 스테판느 혼합 백신 조성물
US6500284B1 (en) 1998-06-10 2002-12-31 Suraltech, Inc. Processes for continuously producing fine grained metal compositions and for semi-solid forming of shaped articles
GB9819898D0 (en) 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
PL201482B1 (pl) 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
KR20010093290A (ko) * 1999-02-05 2001-10-27 폴락 돈나 엘. 사람 파필로마바이러스 백신 제제
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition

Also Published As

Publication number Publication date
GC0000201A (en) 2006-03-29
DE60024893T2 (de) 2006-07-06
IL158107A (en) 2008-11-03
IL158107A0 (en) 2004-03-28
NO20033715L (no) 2002-04-30
ES2253636T3 (es) 2006-06-01
TW200408405A (en) 2004-06-01
CY1106090T1 (el) 2011-06-08
KR100557665B1 (ko) 2006-03-06
ATE321569T1 (de) 2006-04-15
CZ2002843A3 (cs) 2002-08-14
DE60027029T2 (de) 2006-10-19
DK1210113T3 (da) 2006-07-03
US7101560B2 (en) 2006-09-05
ES2261243T3 (es) 2006-11-16
HU229099B1 (en) 2013-07-29
NO2012016I2 (no) 2012-10-08
KR20030087081A (ko) 2003-11-12
HK1048435A1 (en) 2003-04-04
CN1618465A (zh) 2005-05-25
US20040126394A1 (en) 2004-07-01
MY142842A (en) 2011-01-14
CY1107457T1 (el) 2012-12-19
HU228687B1 (en) 2013-05-28
EP1410805B1 (en) 2005-12-14
CZ302811B6 (cs) 2011-11-23
WO2001017551A3 (en) 2001-09-27
EP1210113A2 (en) 2002-06-05
CO5280045A1 (es) 2003-05-30
EP1769806A3 (en) 2007-10-24
GB9921146D0 (en) 1999-11-10
CA2384064C (en) 2010-06-01
SI1410805T1 (sl) 2006-04-30
AR025502A1 (es) 2002-11-27
DE60024893D1 (de) 2006-01-19
NO331825B1 (no) 2012-04-10
BR0014171A (pt) 2002-05-21
IL148456A0 (en) 2002-09-12
US6936255B1 (en) 2005-08-30
NZ527560A (en) 2004-12-24
CN100389824C (zh) 2008-05-28
PT1210113E (pt) 2006-07-31
ZA200201810B (en) 2004-05-26
NO332800B1 (no) 2013-01-14
HUP0202804A3 (en) 2004-08-30
CA2443214A1 (en) 2001-03-15
AU766494B2 (en) 2003-10-16
HUP0303215A3 (en) 2008-04-28
EP1210113B1 (en) 2006-03-29
NO20033715D0 (no) 2003-08-21
US7220551B2 (en) 2007-05-22
EP1769806A2 (en) 2007-04-04
MY130084A (en) 2007-05-31
MXPA02002484A (es) 2002-08-28
ZA200306402B (en) 2004-08-02
US20060280756A1 (en) 2006-12-14
ATE312624T1 (de) 2005-12-15
JP4689910B2 (ja) 2011-06-01
JP2004067696A (ja) 2004-03-04
CN1387443A (zh) 2002-12-25
PL201264B1 (pl) 2009-03-31
PL354039A1 (en) 2003-12-15
HK1048435B (zh) 2007-01-05
HU0303215D0 (en) 2003-11-28
HK1064958A1 (en) 2005-02-08
EP1410805A1 (en) 2004-04-21
CA2384064A1 (en) 2001-03-15
PL201767B1 (pl) 2009-05-29
KR100594668B1 (ko) 2006-06-30
NO2012016I1 (no) 2012-10-15
NO20021116D0 (no) 2002-03-06
DE60027029D1 (de) 2006-05-18
CA2443214C (en) 2006-03-21
CN1325117C (zh) 2007-07-11
TWI258374B (en) 2006-07-21
HUP0202804A2 (hu) 2002-12-28
AU7775100A (en) 2001-04-10
SI1210113T1 (sl) 2006-08-31
WO2001017551A2 (en) 2001-03-15
NO20021116L (no) 2002-04-30
NZ517621A (en) 2003-09-26
JP2003508495A (ja) 2003-03-04
TR200200607T2 (tr) 2002-06-21
KR20020027630A (ko) 2002-04-13
SG110072A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
DK1410805T3 (da) Vaccine mod HPV
NO20014323D0 (no) Vaksine
NO20031483D0 (no) Vaksine
DE60045324D1 (de) Impfstoffzusammensetzung
DK1150712T3 (da) Vaccineformuleringer mod human papillomavirus
DK1326638T3 (da) Vacciner mod cancer
NO20024172D0 (no) Vaksine
CY2011008I2 (el) Εμβολιο γριπης
NO20021433L (no) Vaksiner
DK1210112T3 (da) Vaccine mod HBV og HPV
DE60002650D1 (de) Öladjuvierter Impfstoff
NO20006191D0 (no) Vaksine
DK1139764T3 (da) Adjuvanssammensætning
NO20020763L (no) Vaksine
IS5694A (is) Bóluefni
DK1180041T4 (da) Vaccine mod ISA-virus
DK1105498T3 (da) HIV vaccine
ITMI992410A0 (it) Vaccino per hiv
ITMI981384A0 (it) Vaccino per hiv
NO20002213L (no) Babesia vaksine